本報道最初發表于Endpoints News。請點擊這里查看原文
Pfizer has discontinued its once-daily obesity pill danuglipron after a patient in one of its clinical trials had a liver injury that may have been drug-induced.
因一名臨床試驗受試者出現可能為藥物所致的肝損傷，輝瑞(Pfizer)已停止其每日一次的抗肥胖藥物 danuglipron 的研發。
您已閱讀4%（258字），剩余96%（5966字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。